Neurologic autoimmunity and immune checkpoint inhibitors
暂无分享,去创建一个
C. Klein | S. Markovic | T. Liewluck | V. Lennon | S. Pittock | M. Mauermann | A. McKeon | E. Flanagan | E. Sechi | A. Zekeridou | D. Dubey | A. Lopez-Chiriboga | A. S. Lopez-Chiriboga
[1] S. Pittock,et al. CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. , 2019, JAMA neurology.
[2] A. Pruitt,et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes , 2019, Journal of Neuroimmunology.
[3] R. Sullivan,et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies , 2019, Neurology.
[4] V. Lennon,et al. Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. , 2019, Mayo Clinic proceedings.
[5] H. Lassmann,et al. PDE10A antibodies in autoimmune encephalitis , 2019, Neurology.
[6] C. Lucchinetti,et al. Phosphodiesterase 10A IgG , 2019, Neurology.
[7] F. Ducray,et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[8] D. Scheie,et al. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies , 2018, Neurology.
[9] V. Lennon,et al. Paraneoplastic autoimmunity and small‐cell lung cancer: Neurological and serological accompaniments , 2019, Thoracic cancer.
[10] A. Mammen,et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1 , 2018, Annals of the rheumatic diseases.
[11] C. Lucchinetti,et al. Paraneoplastic neuronal intermediate filament autoimmunity , 2018, Neurology.
[12] S. Minami,et al. Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer , 2018, Case Reports in Neurology.
[13] N. Weiss,et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer , 2018, Neurology.
[14] U. Topaloglu,et al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review , 2018, Journal of Neurology.
[15] S. Irani,et al. Seronegative antibody‐mediated neurology after immune checkpoint inhibitors , 2018, Annals of clinical and translational neurology.
[16] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Sawada,et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report , 2018, BMC Cancer.
[18] M. Lotem,et al. Neurologic complications of immune checkpoint inhibitors , 2018, Journal of Neuro-Oncology.
[19] T. Liewluck,et al. PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies , 2017, Journal of immunotherapy.
[20] M. Mauermann,et al. The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab , 2018, The neurologist.
[21] N. Staff,et al. Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies , 2017, JAMA neurology.
[22] Shigeaki Suzuki,et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan , 2017, Neurology.
[23] N. Staff,et al. Brachial Plexus Neuritis Associated With Anti–Programmed Cell Death-1 Antibodies: Report of 2 Cases , 2017, Mayo Clinic proceedings. Innovations, quality & outcomes.
[24] M. Brown,et al. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy , 2017, Journal of Neuroimmunology.
[25] S. Cuzzubbo,et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. , 2017, European journal of cancer.
[26] M. Garg,et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy , 2017, Front. Pharmacol..
[27] J. Larkin,et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] V. Lennon,et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. , 2016, JAMA neurology.
[29] E. Lipson,et al. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. , 2016, JAMA neurology.
[30] C. Berking,et al. CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis , 2016, Annals of neurology.
[31] V. Lennon,et al. Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma. , 2016, JAMA neurology.
[32] S. Yeh,et al. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. , 2015, Journal of immunotherapy.
[33] K. Murphy,et al. New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment , 2014, Oncology Research and Treatment.
[34] Antoni Ribas,et al. Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.
[35] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[36] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[37] S. Pittock,et al. CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. , 2019, JAMA neurology.
[38] A. Pruitt,et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes , 2019, Journal of Neuroimmunology.
[39] R. Sullivan,et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies , 2019, Neurology.
[40] V. Lennon,et al. Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. , 2019, Mayo Clinic proceedings.
[41] F. Ducray,et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[42] D. Scheie,et al. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies , 2018, Neurology.
[43] V. Lennon,et al. Paraneoplastic autoimmunity and small‐cell lung cancer: Neurological and serological accompaniments , 2019, Thoracic cancer.
[44] A. Mammen,et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1 , 2018, Annals of the rheumatic diseases.
[45] C. Lucchinetti,et al. Paraneoplastic neuronal intermediate filament autoimmunity , 2018, Neurology.
[46] S. Minami,et al. Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer , 2018, Case Reports in Neurology.
[47] N. Weiss,et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer , 2018, Neurology.
[48] U. Topaloglu,et al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review , 2018, Journal of Neurology.
[49] S. Irani,et al. Seronegative antibody‐mediated neurology after immune checkpoint inhibitors , 2018, Annals of clinical and translational neurology.
[50] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Sawada,et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report , 2018, BMC Cancer.
[52] M. Lotem,et al. Neurologic complications of immune checkpoint inhibitors , 2018, Journal of Neuro-Oncology.
[53] T. Liewluck,et al. PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies , 2017, Journal of immunotherapy.
[54] M. Mauermann,et al. The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab , 2018, The neurologist.
[55] N. Staff,et al. Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies , 2017, JAMA neurology.
[56] Shigeaki Suzuki,et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan , 2017, Neurology.
[57] N. Staff,et al. Brachial Plexus Neuritis Associated With Anti–Programmed Cell Death-1 Antibodies: Report of 2 Cases , 2017, Mayo Clinic proceedings. Innovations, quality & outcomes.
[58] M. Brown,et al. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy , 2017, Journal of Neuroimmunology.
[59] S. Cuzzubbo,et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. , 2017, European journal of cancer.
[60] M. Garg,et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy , 2017, Front. Pharmacol..
[61] V. Lennon,et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. , 2016, JAMA neurology.
[62] J. Larkin,et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] E. Lipson,et al. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. , 2016, JAMA neurology.
[64] C. Berking,et al. CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis , 2016, Annals of neurology.
[65] V. Lennon,et al. Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma. , 2016, JAMA neurology.
[66] S. Yeh,et al. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. , 2015, Journal of immunotherapy.
[67] K. Murphy,et al. New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment , 2014, Oncology Research and Treatment.
[68] Antoni Ribas,et al. Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.
[69] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[70] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.